We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...
Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...
A head-to-head, randomized study of the two leading heart implants worldwide for reducing the risk of stroke among people with an irregular pulse found there was little difference between their safety ...
Abbott Laboratories (NYSE:ABT) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 6, Abbott Laboratories (NYSE:ABT) released positive clinical trial results for its Amulet 360 ...
Five late-breaking presentations at TCT 2022 highlight the impact of Abbott (ABT)'s structural heart devices to repair or replace heart valves and close openings in the heart New data reinforce the ...
SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results